Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions
ALNY Stock Forecast
Alnylam Pharmaceuticals stock forecast is as follows: an average price target of $254.21 (represents a 7.92% upside from ALNY’s last price of $235.56) and a rating consensus of 'Buy', based on 22 wall street analysts offering a 1-year stock forecast.
ALNY Price Target
The average price target for Alnylam Pharmaceuticals (ALNY) is $254.21 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $96.00. This represents a potential 7.92% upside from ALNY's last price of $235.56.
ALNY Analyst Ratings
According to 22 Wall Street analysts, Alnylam Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ALNY stock is 0 'Strong Buy' (0.00%), 17 'Buy' (77.27%), 4 'Hold' (18.18%), 1 'Sell' (4.55%), and 0 'Strong Sell' (0.00%).
Alnylam Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | Whitney Ijem | Canaccord Genuity | $336.00 | $294.87 | 13.95% | 42.64% |
| Oct 01, 2024 | Whitney Ijem | Canaccord Genuity | $366.00 | $273.69 | 33.73% | 55.37% |
| Sep 27, 2024 | Tazeen Ahmad | Bank of America Securities | $307.00 | $274.91 | 11.67% | 30.33% |
| Aug 27, 2024 | Kostas Biliouris | BMO Capital | $300.00 | $269.31 | 11.40% | 27.36% |
| Aug 26, 2024 | Luca Issi | RBC Capital | $300.00 | $271.43 | 10.53% | 27.36% |
| Aug 16, 2024 | Salveen Richter | Goldman Sachs | $370.00 | $262.70 | 40.85% | 57.07% |
| Jul 08, 2024 | Whitney Ijem | Canaccord Genuity | $357.00 | $253.86 | 40.63% | 51.55% |
| Jun 28, 2024 | Esther Rajavelu | UBS | $288.00 | $247.00 | 16.60% | 22.26% |
| Jun 27, 2024 | Luca Issi | RBC Capital | $265.00 | $245.17 | 8.09% | 12.50% |
| Jun 27, 2024 | Paul Matteis | Stifel Nicolaus | $295.00 | $247.40 | 19.24% | 25.23% |
The latest Alnylam Pharmaceuticals stock forecast, released on Oct 24, 2024 by Whitney Ijem from Canaccord Genuity, set a price target of $336.00, which represents a 13.95% increase from the stock price at the time of the forecast ($294.87), and a 42.64% increase from ALNY last price ($235.56).
Alnylam Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 5 | 17 |
| Avg Price Target | $336.00 | $321.80 | $297.65 |
| Last Closing Price | $235.56 | $235.56 | $235.56 |
| Upside/Downside | 42.64% | 36.61% | 26.36% |
In the current month, the average price target of Alnylam Pharmaceuticals stock is $336.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 42.64% increase as opposed to Alnylam Pharmaceuticals's last price of $235.56. This month's average price target is up 4.41% compared to last quarter, and up 12.88% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 01, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 27, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Sep 03, 2024 | Oppenheimer | Perform | Perform | Hold |
| Sep 03, 2024 | Wolfe Research | Negative | Negative | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Barclays | Overweight | Overweight | Hold |
Alnylam Pharmaceuticals's last stock rating was published by Canaccord Genuity on Oct 24, 2024. The company gave ALNY a "Buy" rating, the same as its previous rate.
Alnylam Pharmaceuticals Financial Forecast
Alnylam Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $750.53M | - | $319.29M | $335.04M | $264.31M | $224.82M | $213.26M | $258.54M | $187.63M | $220.55M | $177.57M | $163.56M | $125.85M | $103.96M | $99.48M | $71.68M | $70.06M |
| Avg Forecast | $997.48M | $944.74M | $823.90M | $777.35M | $778.22M | $660.23M | $576.49M | $554.43M | $579.59M | $532.91M | $447.22M | $428.01M | $436.92M | $396.76M | $332.28M | $312.27M | $313.13M | $291.66M | $255.56M | $240.95M | $233.61M | $218.72M | $192.05M | $168.50M | $146.64M | $119.05M | $98.76M | $91.74M | $71.60M | $57.17M |
| High Forecast | $1.14B | $1.08B | $945.16M | $891.76M | $892.75M | $757.40M | $661.33M | $596.97M | $669.61M | $539.25M | $447.22M | $428.01M | $483.30M | $647.63M | $381.18M | $358.23M | $359.22M | $291.66M | $255.56M | $240.95M | $233.61M | $218.72M | $192.05M | $168.50M | $146.64M | $119.05M | $98.76M | $91.74M | $71.60M | $57.17M |
| Low Forecast | $909.19M | $861.12M | $750.97M | $708.54M | $709.33M | $601.79M | $525.46M | $509.84M | $535.39M | $526.57M | $447.22M | $428.01M | $371.99M | $327.97M | $302.86M | $284.63M | $285.42M | $291.66M | $255.56M | $240.95M | $233.61M | $218.72M | $192.05M | $168.50M | $146.64M | $119.05M | $98.76M | $91.74M | $71.60M | $57.17M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 5 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.89% | - | 1.02% | 1.07% | 0.91% | 0.88% | 0.89% | 1.11% | 0.86% | 1.15% | 1.05% | 1.12% | 1.06% | 1.05% | 1.08% | 1.00% | 1.23% |
Alnylam Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 11 analysts is $436.92M, with a low forecast of $371.99M, and a high forecast of $483.30M. ALNY's average Quarter revenue forecast represents a -41.79% decrease compared to the company's last Quarter revenue of $750.53M (Sep 23).
Alnylam Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 5 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $213.87M | - | $-143.41M | $-177.11M | $-234.69M | $-168.50M | $-142.59M | $-202.03M | $-140.74M | $-132.75M | $-143.90M | $-194.20M | $-204.95M | $-132.88M | $-159.16M | $-254.57M | $-181.39M |
| Avg Forecast | $-761.67M | $-721.40M | $-629.12M | $-593.58M | $-594.24M | $-504.14M | $-440.20M | $-423.36M | $-442.57M | $-406.93M | $-341.49M | $-207.18M | $-333.63M | $-302.96M | $-253.72M | $-188.35M | $-320.71M | $-223.23M | $-195.60M | $-171.23M | $-178.80M | $-167.40M | $-146.99M | $-155.94M | $-112.24M | $-91.12M | $-75.59M | $-188.16M | $-54.80M | $-43.76M |
| High Forecast | $-694.25M | $-657.54M | $-573.44M | $-541.04M | $-541.64M | $-459.52M | $-401.24M | $-389.31M | $-408.82M | $-402.09M | $-341.49M | $-165.75M | $-284.05M | $-250.43M | $-231.26M | $-150.68M | $-256.57M | $-223.23M | $-195.60M | $-136.98M | $-178.80M | $-167.40M | $-146.99M | $-124.75M | $-112.24M | $-91.12M | $-75.59M | $-150.53M | $-54.80M | $-43.76M |
| Low Forecast | $-873.77M | $-827.57M | $-721.71M | $-680.94M | $-681.70M | $-578.34M | $-504.99M | $-455.84M | $-511.31M | $-411.77M | $-341.49M | $-248.62M | $-369.04M | $-494.52M | $-291.06M | $-226.02M | $-384.85M | $-223.23M | $-195.60M | $-205.47M | $-178.80M | $-167.40M | $-146.99M | $-187.13M | $-112.24M | $-91.12M | $-75.59M | $-225.79M | $-54.80M | $-43.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.71% | - | 0.76% | 0.55% | 1.05% | 0.86% | 0.83% | 1.13% | 0.84% | 0.90% | 0.92% | 1.73% | 2.25% | 1.76% | 0.85% | 4.65% | 4.15% |
11 analysts predict ALNY's average Quarter EBITDA for Dec 23 to be $-333.63M, with a high of $-284.05M and a low of $-369.04M. This is -256.00% lower than Alnylam Pharmaceuticals's previous annual EBITDA (Sep 23) of $213.87M.
Alnylam Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 5 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $147.75M | - | $-174.10M | $-207.49M | $-405.92M | $-277.40M | $-240.34M | $-258.46M | $-204.51M | $-189.56M | $-200.29M | $-243.54M | $-253.29M | $-179.23M | $-182.22M | $-276.19M | $-208.53M |
| Avg Forecast | $189.36M | $156.03M | $77.73M | $57.29M | $8.22M | $-59.56M | $-94.23M | $-88.15M | $-75.41M | $-117.87M | $-137.21M | $-265.52M | $-152.55M | $-185.90M | $-193.64M | $-241.39M | $-165.94M | $-220.89M | $-200.88M | $-219.44M | $-195.95M | $-194.77M | $-203.41M | $-202.61M | $-225.49M | $-206.21M | $-218.50M | $-208.25M | $-280.22M | $-262.76M |
| High Forecast | $225.59M | $185.88M | $92.61M | $68.25M | $9.80M | $-52.71M | $-83.38M | $-45.59M | $66.36M | $-104.31M | $-121.42M | $-212.42M | $6.36M | $91.58M | $-171.36M | $-193.11M | $-132.75M | $-220.89M | $-200.88M | $-175.55M | $-195.95M | $-194.77M | $-203.41M | $-162.09M | $-225.49M | $-206.21M | $-218.50M | $-166.60M | $-280.22M | $-262.76M |
| Low Forecast | $167.57M | $138.08M | $68.79M | $50.70M | $7.28M | $-70.96M | $-112.25M | $-123.10M | $-202.11M | $-140.42M | $-163.46M | $-318.63M | $-391.56M | $-265.18M | $-230.69M | $-289.66M | $-199.13M | $-220.89M | $-200.88M | $-263.33M | $-195.95M | $-194.77M | $-203.41M | $-243.13M | $-225.49M | $-206.21M | $-218.50M | $-249.90M | $-280.22M | $-262.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.79% | - | 0.72% | 1.25% | 1.84% | 1.38% | 1.10% | 1.32% | 1.05% | 0.93% | 0.99% | 1.08% | 1.23% | 0.82% | 0.88% | 0.99% | 0.79% |
Alnylam Pharmaceuticals's average Quarter net income forecast for Dec 23 is $-152.55M, with a range of $-391.56M to $6.36M. ALNY's average Quarter net income forecast represents a -203.25% decrease compared to the company's last Quarter net income of $147.75M (Sep 23).
Alnylam Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 5 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $199.18M | - | $183.66M | $210.34M | $235.86M | $169.98M | $154.47M | $186.38M | $142.07M | $145.32M | $146.86M | $166.29M | $167.47M | $127.90M | $126.76M | $156.28M | $120.35M |
| Avg Forecast | $1.05B | $998.94M | $871.16M | $821.94M | $822.86M | $698.10M | $609.56M | $586.24M | $612.84M | $563.48M | $472.88M | $170.66M | $461.98M | $419.52M | $351.34M | $155.14M | $119.66M | $308.39M | $270.22M | $141.04M | $247.01M | $231.27M | $203.07M | $148.56M | $155.05M | $125.88M | $104.43M | $97.00M | $75.71M | $60.45M |
| High Forecast | $1.21B | $1.15B | $999.38M | $942.91M | $943.97M | $800.85M | $699.27M | $631.21M | $708.02M | $570.18M | $472.88M | $204.79M | $511.02M | $684.78M | $403.04M | $186.17M | $143.60M | $308.39M | $270.22M | $169.25M | $247.01M | $231.27M | $203.07M | $178.27M | $155.05M | $125.88M | $104.43M | $97.00M | $75.71M | $60.45M |
| Low Forecast | $961.35M | $910.52M | $794.05M | $749.19M | $750.03M | $636.31M | $555.60M | $539.08M | $566.10M | $556.78M | $472.88M | $136.53M | $393.33M | $346.78M | $320.24M | $124.11M | $95.73M | $308.39M | $270.22M | $112.83M | $247.01M | $231.27M | $203.07M | $118.85M | $155.05M | $125.88M | $104.43M | $97.00M | $75.71M | $60.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.47% | - | 1.18% | 1.76% | 0.76% | 0.63% | 1.10% | 0.75% | 0.61% | 0.72% | 0.99% | 1.07% | 1.33% | 1.22% | 1.31% | 2.06% | 1.99% |
Alnylam Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $461.98M, based on 11 Wall Street analysts, with a range of $393.33M to $511.02M. The forecast indicates a 131.95% rise compared to ALNY last annual SG&A of $199.18M (Sep 23).
Alnylam Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 16 | 8 | 5 | 10 | 11 | 17 | 8 | 8 | 7 | 7 | 12 | 7 | 14 | 8 | 9 | 15 | 10 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.18 | - | $-1.40 | $-1.68 | $-3.32 | $-2.29 | $-2.00 | $-2.16 | $-1.72 | $-1.61 | $-1.71 | $-2.09 | $-2.18 | $-1.56 | $-1.62 | $-2.47 | $-1.92 |
| Avg Forecast | $1.47 | $1.21 | $0.60 | $0.45 | $0.06 | $-0.46 | $-0.73 | $-0.69 | $-0.59 | $-0.92 | $-1.07 | $-1.12 | $-1.19 | $-1.45 | $-1.51 | $-1.67 | $-1.86 | $-1.74 | $-1.59 | $-1.81 | $-1.55 | $-1.54 | $-1.61 | $-1.75 | $-1.78 | $-1.63 | $-1.72 | $-1.89 | $-2.21 | $-2.07 |
| High Forecast | $1.75 | $1.45 | $0.72 | $0.53 | $0.08 | $-0.41 | $-0.65 | $-0.35 | $0.52 | $-0.81 | $-0.94 | $-0.99 | $0.05 | $0.71 | $-1.33 | $-1.48 | $-1.65 | $-1.74 | $-1.59 | $-1.81 | $-1.55 | $-1.54 | $-1.61 | $-1.75 | $-1.78 | $-1.63 | $-1.72 | $-1.89 | $-2.21 | $-2.07 |
| Low Forecast | $1.30 | $1.07 | $0.53 | $0.39 | $0.06 | $-0.55 | $-0.87 | $-0.96 | $-1.57 | $-1.09 | $-1.27 | $-1.33 | $-3.04 | $-2.06 | $-1.79 | $-1.99 | $-2.21 | $-1.74 | $-1.59 | $-1.81 | $-1.55 | $-1.54 | $-1.61 | $-1.75 | $-1.78 | $-1.63 | $-1.72 | $-1.89 | $-2.21 | $-2.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.82% | - | 0.84% | 0.90% | 1.90% | 1.44% | 1.11% | 1.40% | 1.12% | 1.00% | 0.98% | 1.17% | 1.34% | 0.90% | 0.86% | 1.12% | 0.93% |
According to 11 Wall Street analysts, Alnylam Pharmaceuticals's projected average Quarter EPS for Dec 23 is $-1.19, with a low estimate of $-3.04 and a high estimate of $0.05. This represents a -200.54% decrease compared to ALNY previous annual EPS of $1.18 (Sep 23).
Alnylam Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.75 | $106.93 | 138.95% | Buy |
| WVE | Wave Life Sciences | $13.67 | $22.14 | 61.96% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| HALO | Halozyme Therapeutics | $45.65 | $57.00 | 24.86% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.76 | $5.33 | 11.97% | Buy |
| KRYS | Krystal Biotech | $170.74 | $191.00 | 11.87% | Buy |
| INCY | Incyte | $75.87 | $84.56 | 11.45% | Buy |
| MDGL | Madrigal Pharmaceuticals | $288.58 | $315.75 | 9.42% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| UTHR | United Therapeutics | $363.25 | $358.20 | -1.39% | Buy |
| PRQR | ProQR Therapeutics | $3.82 | $3.63 | -4.97% | Buy |
| EXEL | Exelixis | $34.45 | $30.50 | -11.47% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |